Interesting work Tuck.
trca, could be a bigger market potential than you think. But will 2 injections/day be a barrier to penetrating a broader market? How many injections is HGH? I think this is where insm has an advantage, binding to the second antibody extends the duration? Also being one of the chopped ipo's they'll need cash in the next year.
cgtk, more a device ala stents. I bought a smidge, but it's terribly risky. If it bombs, tax loss city.
I was poking through the S1 for Momenta which is supposed to ipo this week. I met the ceo while he was at mlnm and know people who speak very highly of him and find their sugar technology to be very interesting. A true stretch for them to be public, as they have *nothing* in the clinic. Have spent just $5M on r&d since inception though that wouldn't include the cost of developing the tech in academia or whereever they got it. Working on an anda for lovenox with Sandoz. Yet another inhaled insulin play, but, they claim to have ***99%*** bioavailability in animals. Astounding if it bears out in humans. Inhaled insulin, hgh, epo listed as early programs.
Biocentury a few months ago ran an interesting cover story tracking bio returns post ipo. The best returns came from the lowest market cap ipo's (<$200M) as opposed to the bigger money more hyped ipo's. So who knows, maybe a few good ones will emerge from this tepid group. |
